Evaluación positiva de medicamentos: marzo, abril, mayo, junio y julio de 2021
Sanid. mil. 2021; 77(4) 217
noleukodystrophy (CALD). Clinicaltrials.gov. Consultado el 04/08/2021.
Disponible en: https://clinicaltrials.gov/ct2/show/NCT01896102?term=ALD-
102&draw=2&rank=1.
17. Kernel Networks Inc. Clinical study to assess the efficacy and safety of gene
therapy for the treatment of cerebral adrenoleukodystrophy (CALD). Clinicaltrials.
gov. Consultado el 04/08/2021. Disponible en: https://clinicaltrials.
gov/ct2/show/NCT03852498?term=ALD-104&draw=2&rank=1.
18. European Medicines Agency. EPAR-Product Information of Lydisilka®.
Consultado 04/08/2021. Disponible en: https://www.ema.europa.eu/en/
documents/assessment-report/lydisilka-epar-public-assessment-report_
en.pdf.
19. European Medicines Agency. EPAR-Product Information of Drovelis®.
Consultado 04/08/2021. Disponible en: https://www.ema.europa.eu/en/documents/
assessment-report/drovelis-epar-public-assessment-report_en.pdf.
20. E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/
Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/
Russia Study. Clinicaltrials.gov. Consultado 04/08/2021. Disponible en:
https://clinicaltrials.gov/ct2/show/NCT02817828?term=MIT-Es0001-
C301&draw=2&rank=1.
21. E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/
Drospirenone as Oral Contraceptive in a Multicentric Study) - United
States/Canada Study. Clinicaltrials.gov. Consultado 04/08/2021. Disponible en:
https://clinicaltrials.gov/ct2/show/results/NCT02817841?term=MIT-Es0001-
C302&draw=2&rank=1.
22. European Medicines Agency. EPAR-Product Information of Evkeeza®.
Consultado 04/08/2021. Disponible en: https://www.ema.europa.eu/en/documents/
assessment-report/evkeeza-h-c-5449-0000-epar-assessment-report_
en.pdf.
23. Efficacy and Safety of Evinacumab in Patients With Homozygous Familial
Hypercholesterolemia. Clinicaltrials.gov. Consultado el 04/08/2021. Disponible
en: https://clinicaltrials.gov/ct2/show/NCT03399786?term=R1500-CL-
1629&draw=2&rank=1.
24. European Medicines Agency. EPAR-Product Information of Efmody®.
Consultado 04/08/2021. Disponible en: https://www.ema.europa.eu/en/documents/
assessment-report/efmody-epar-ublic-assessment-report_en.pdf.
25. Comparison of Chronocort® With Standard Glucocorticoid Therapy in
Patients With Congenital Adrenal Hyperplasia. Clinicaltrials.gov. Consultado
04/08/2021. Disponible en: https://clinicaltrials.gov/ct2/show/results/
NCT02716818?term=DIUR-005&draw=2&rank=2.
26. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Reunión
del Comité de Medicamentos de Uso Humano (CHMP) de junio 2021.
Disponible en: https://www.aemps.gob.es/informa/boletines-aemps/boletinchmp/
2021-boletin-chmp/reunion-del-comite-de-medicamentos-de-uso-humano
chmp-de-junio-2021/.
27. European Medicines Agency. Summary of opinion: Abecma. Disponible en:
https://www.ema.europa.eu/en/medicines/human/summaries-opinion/abecma.
28. Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al.
Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl
J Med. 2021; 384(8): 705-16.
29. European Medicines Agency. Summary of opinion: Imatinib Koanaa. Disponible
en: https://www.ema.europa.eu/en/medicines/human/summariesopinion/
imatinib-koanaa.
30. Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica
Glivec. Consultado 05/08/2021. Disponible en: https://cima.aemps.es/cima/
dochtml/ft/01198008/FT_01198008.html.
31. European Medicines Agency. EPAR-Product Information of Klisyri®. Consultado
05/08/2021. Disponible en: https://www.ema.europa.eu/en/documents/
assessment-report/klisyri-epar-assessment-report_en.pdf.
32. Blauvelt A, Kempers S, Lain E, Schlesinger T, Tyring S, Forman S, et al.
Phase 3 trials of tirbanibulin ointment for actinic keratosis. N Engl J Med
2021; 384: 512-20.
33. European Medicines Agency. EPAR-Product Information of Bylvay®. Consultado
05/08/2021. Disponible en: https://www.ema.europa.eu/en/documents/
assessment-report/bylvay-epar-public-assessment-report_en.pdf.
34. Jayanta Roy-Chowdhury. Inherited disorders associated with conjugated hyperbilirubinemia.
En: UpToDate, Post TW (Ed), UpToDate, Waltham, MA.
(accedido el 5 de agosto de 2021).
35. European Medicines Agency. Summary of opinion: Ozawade. Disponible en:
https://www.ema.europa.eu/en/medicines/human/summaries-opinion/ozawade.
36. Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica
Wakix. Consultado 05/08/2021. Disponible en: https://cima.aemps.es/cima/
dochtml/ft/1151068002/FT_1151068002.html.
37. Pépin J-L, Georgiev O, Tiholov R, Attali V, Verbraecken J, Buyse B, et al.
Pitolisant for residual excessive daytime sleepiness in OSA patients adhering
to CPAP: A randomized trial. Chest 2021; 159: 1598-609.
38. European Medicines Agency. EPAR-Product Information of Ponvory®.
Consultado 09/08/2021. Disponible en: https://www.ema.europa.eu/en/documents/
assessment-report/ponvory-epar-public-assessment-report_en.pdf.